Most of Israel "Izzy" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd ...
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
BioAge (BIOA) stock cratered 70% Friday evening after the company said it was discontinuing a Phase 2 study for its ...
BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's tirzepatide for the treatment of obesity.
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
According to projections, the global market for obesity drugs could be worth nearly $14 billion by 2032. Zepbound has already ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...